Biotechnology Synthesis — Evaluating Benefit, Risk and Biodiversity

Q1 — Sample Band 6 response (9 marks), annotated

Biotechnology should be evaluated through a framework that weighs benefit, risk, biodiversity effect and stakeholder impact together, then concludes conditionally. Whether biotechnology benefits society without compromising biodiversity depends on the specific case — medical, agricultural or animal — and the context of use. [1 — framework + thesis]

Medical case — CRISPR therapy for sickle-cell disease. The direct benefit is curative: edited haematopoietic stem cells produce functional haemoglobin in patients with an otherwise lifelong disease. The main risks Card 2 highlights for medical biotechnology — access, cost, safety, consent — are all live concerns (off-target editing, multi-million-dollar treatment cost limits access). Stakeholders include patients, public health systems and insurers; the distribution is currently inequitable. Biodiversity impact: negligible at the population biodiversity level, because the somatic edit is not heritable. Judgement: to a large extent the technology is highly beneficial, provided that access is broadened and safety profiles continue to mature. [1 — case 1 framework + named biodiversity level]

Agricultural case — Bt cotton (insecticidal transgenic cultivar). Benefit: reduced bollworm damage and reduced broad-spectrum pesticide use in the short term. Risks: pest evolution of Bt-resistance (documented in pink bollworm), seed ownership concentrating on one supplier, smallholder dependence. Stakeholders: smallholder farmers, seed companies, downstream consumers and non-target invertebrate communities. Biodiversity impact: at the genetic level, on-farm allelic diversity in the crop is reduced; at the species/ecosystem level, monoculture and altered pesticide regimes affect non-target invertebrates. Judgement: beneficial in many contexts, but the biodiversity trade-off is real unless diversity is maintained at the farm and landscape scale. [1 — case 2 framework + biodiversity level + named risk]

Animal case — gene drive against invasive black rats on a seabird-breeding island. Benefit: recovery of native seabird species (a biodiversity benefit). Risks: drive escape to non-target populations, irreversibility, welfare concerns about engineered infertility. Stakeholders: conservation agency, surrounding fisheries, indigenous landowners. Biodiversity impact: positive at the species and ecosystem level on the target island; potentially negative if the drive escapes to mainland or other populations. Judgement: justified provided that escape pathways are eliminated, the drive is reversible and stakeholders are consulted. [1 — case 3 framework + biodiversity level + stakeholder fairness]

Comparative synthesis. Three cases produce three different balances. The medical case has high direct benefit and low biodiversity cost. The agricultural case has a moderate benefit but a genuine genetic-level biodiversity cost. The animal case has a strong biodiversity benefit when geographically contained, but high ecosystem-level risk if the drive escapes. [1 — explicit comparison across cases] A single universal verdict is therefore unjustified: the same word "biotechnology" describes interventions whose biodiversity impact differs by orders of magnitude. [1 — synthesis explicitly rejects one universal verdict]

Qualified judgement. To a large extent, biotechnology can benefit society without compromising biodiversity in medical applications, provided that access is fairly distributed. In agricultural applications its value depends on whether genetic diversity is maintained at the farm and landscape scale. In conservation applications it can actively support biodiversity, provided that escape and irreversibility risks are managed. The overall judgement must be conditional and case-by-case rather than absolute. [1 — explicitly qualified, comparative final judgement]

Marking criteria.

• 1 mark — Sets up the five-step framework explicitly OR uses it as the organising spine of the response.
• 1 mark — Medical case: named example (e.g. CRISPR sickle-cell therapy, recombinant insulin) + biodiversity level explicitly identified.
• 1 mark — Agricultural case: named example (e.g. Bt cotton, GM canola, Golden Rice) + genetic / species / ecosystem level identified + at least one named risk (resistance, monoculture, ownership).
• 1 mark — Animal case: named example (e.g. transgenic livestock, gene drive against invasive species, cloned animals) + at least one stakeholder identified.
• 1 mark — At least one explicit stakeholder analysis (who benefits / who carries risk) somewhere in the response.
• 1 mark — Comparative synthesis paragraph that shows the three cases produce different balances (not one universal verdict).
• 1 mark — Final judgement uses explicit conditional language ("to a large extent", "provided that", "depends on") consistent with Card 4.
• 1 mark — Final judgement is per-context (not collapsed to a single verdict across all three cases).
• 1 mark — Response uses precise lesson terminology throughout (synthesis, qualified judgement, stakeholder, biodiversity level, trade-off).

Q2 — Source critique (8 marks)

2.1 Shared reliability weaknesses (2 marks). Both sources are non-peer-reviewed (a company press release and an anonymous campaign blog) and conflicted (commercial interest vs activist agenda), so neither qualifies as primary scientific evidence [1]. Both use absolutist language ("Every nutritionist agrees…", "Trust no biotechnology") that Card 4 explicitly identifies as the marker of a weak judgement; both also fail to compare cases or contexts [1]. Accept any two of: absent citations, absent data, emotive language, single-source reasoning.

2.2 Unsupported claims (2 marks). Source A: "no biodiversity risks because rice is already grown everywhere" is unsupported — Card 3 requires the student to specify whether genetic, species or ecosystem diversity is affected, and large-scale planting of one cultivar reduces on-farm genetic diversity in the rice gene pool [1]. Source B: "Trust no biotechnology" and "No GM crop has ever been safe" are absolutist and contradicted by Module 6 cases such as recombinant insulin, which has been clinically used safely for decades [1]. Accept other valid identifications, each scored on whether they connect to a lesson principle.

2.3 Balanced one-paragraph synthesis (4 marks). Sample: "Golden Rice expresses β-carotene in the grain, offering a genuine medical/nutritional benefit by addressing vitamin A deficiency [1 — benefit acknowledged, à la Source A]. However, the agricultural-biotech evaluation issues identified in Card 2 still apply: at the genetic level, displacement of traditional rice landraces would reduce on-farm allelic diversity, and at the stakeholder level, smallholder farmers may face dependence on a single seed supplier — concerns Source B is right to raise even though it overstates them [1 — biodiversity level + stakeholder issue]. Comparing Golden Rice with recombinant insulin (a medical case with low biodiversity cost) and gene-drive conservation (an animal case with high ecosystem benefit) shows that 'biotechnology' is not one thing and one verdict cannot fit all three [1 — comparative case use]. Therefore, to a large extent Golden Rice can benefit society provided that traditional landraces are preserved alongside it and seed access remains equitable; the technology's value depends on biodiversity and stakeholder safeguards, not on either source's absolute verdict [1 — qualified judgement with explicit conditional]."

Marking criteria. 2.1: 1 mark each for two distinct reliability weaknesses (peer-review status, conflict of interest, absolutist language, missing data, single-source reasoning, emotive framing). 2.2: 1 mark per source for identifying a specific claim that fails the framework (productivity-only / "no biodiversity risk" / absolute "all GM is unsafe") with reasoning. 2.3: 1 mark for benefit acknowledged; 1 mark for biodiversity level + stakeholder concern named; 1 mark for at least one comparison to another Module 6 case; 1 mark for an explicitly qualified final judgement.

Q3 — Sample Band 6 response (6 marks)

The claim is partly defensible but structurally flawed. It collapses heterogeneous cases into one verdict — exactly the error Card 2 and Card 4 of the lesson warn against. [1 — overall judgement]

What is defensible: Many Module 6 technologies do provide major benefits. Recombinant insulin (Lessons on recombinant DNA technology) gives reliable human insulin to people with diabetes, replacing animal-derived sources; PCR (early Module 6 lessons) is foundational to modern diagnostics including non-invasive prenatal testing; CRISPR-based therapy for sickle-cell disease can be curative. [1 — concedes one defensible element with named cases]

What is wrong — case 1, Bt cotton / transgenic crops (Module 6 agricultural-biotech thread). A "single verdict" hides the genetic-level diversity loss that monoculture planting can cause, plus pest resistance evolution and seed-ownership dependence. The biodiversity issue is not an "edge case" — it is the central evaluation issue Card 2 names for agricultural biotechnology. [1 — agricultural case refutation]

What is wrong — case 2, gene drives for invasive species control (Module 6 biodiversity thread, Lessons 10–11). A gene drive can produce a large biodiversity benefit on a target island, but its risks (escape to non-target populations, irreversibility) operate at the ecosystem level and would be catastrophic if realised. Calling this an "edge case" misrepresents both the magnitude of benefit and the magnitude of risk. [1 — animal/conservation case refutation]

What is wrong — case 3, CRISPR therapeutics (Module 6 medical-biotech thread). Even within medical biotechnology, the access/cost issue means the same technology has different value for different stakeholders. Card 2 specifically names access, cost, safety and consent as the live evaluation issues — they are not edge cases. [1 — medical case refutation including stakeholder issue]

Defensible reformulation: "The biotechnologies covered in Module 6 do not share a single verdict. Each must be evaluated on benefit, risk, biodiversity level (genetic, species or ecosystem) and stakeholder impact in its own context. Many cases benefit society to a large extent provided that the specific risks named in Card 2 — access for medical cases, monoculture and ownership for agricultural cases, welfare and escape for animal cases — are actively managed." [1 — biologically defensible, qualified, multi-case reformulation]

Marking criteria.

• 1 mark — Reaches an overall evaluative judgement (e.g. "partly defensible but structurally flawed").
• 1 mark — Concedes the defensible element with at least one named Module 6 case (e.g. recombinant insulin, PCR, CRISPR therapy).
• 1 mark — Refutes the claim using a specific agricultural-biotech case (Bt cotton, GM canola, Golden Rice) with a named biodiversity level or risk.
• 1 mark — Refutes the claim using a specific animal / conservation case (gene drive, transgenic livestock, cloned animals).
• 1 mark — Refutes the claim using a specific medical-biotech case with stakeholder reasoning (access, cost, consent).
• 1 mark — Reformulates the claim into a case-by-case, qualified statement using conditional language consistent with Card 4.